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Somatostatin analogues, which are used to treat neu-
roendocrine tumors, target the high levels of soma-
tostatin receptor subtype 2 (SSTR1; alias sst2) ex-
pressed in these cancers. However, some tumors are
resistant to somatostatin analogues, and it is un-
known whether the defect lies in sst2 activation or
downstream signaling events. Because sst2 phosphor-
ylation occurs rapidly after receptor activation, we
examined whether sst2 is phosphorylated in neu-
roendocrine tumors. The sst2 receptor phosphoryla-
tion was evaluated by IHC and Western blot analysis
with the new Ra-1124 antibody specific for the sst2
receptor phosphorylated at Ser341/343 in receptor-
positive neuroendocrine tumors obtained from 10 oc-
treotide-treated and 7 octreotide-naïve patients. The
specificity, time course, and subcellular localization
of sst2 receptor phosphorylation were examined in
human embryo kinase–sst2 cell cultures by immuno-
fluorescence and confocal microscopy. All seven oc-
treotide-naïve tumors displayed exclusively nonphos-
phorylated cell surface sst2 expression. In contrast, 9
of the 10 octreotide-treated tumors contained phos-
phorylated sst2 that was predominantly internalized.
Western blot analysis confirmed the IHC data. Oc-
treotide treatment of human embryo kinase–sst2 cells
in culture demonstrated that phosphorylated sst2 was
localized at the plasma membrane after 10 seconds of
stimulation and was subsequently internalized into en-
docytic vesicles. These data show, for the first time to
our knowledge, that phosphorylated sst2 is present in
most gastrointestinal neuroendocrine tumors from pa-
tients treated with octreotide but that a striking variabil-
ity exists in the subcellular distribution of phosphory-
1942lated receptors among such tumors. (Am J Pathol 2012,
180:1942–1949; DOI: 10.1016/j.ajpath.2012.01.041)
Somatostatin receptors are overexpressed in most neu-
roendocrine tumors.1 This has led to two clinical applica-
tions. First, somatostatin analogues, such as octreotide or
lanreotide, can functionally inhibit the excess hormone re-
lease and the further growth of these tumors.2,3 Second,
radiolabeled somatostatin analogues can be used for diag-
nostic imaging of the tumors and targeted radiotherapy.4,5
As the predominantly expressed somatostatin receptor
subtype, the somatostatin receptor subtype 2 (SSTR1; alias
sst2) has been detected immunohistochemically (IHC) in
neuroendocrine tumors, usually at the tumor cell mem-
brane.6–8 This histopathological diagnosis has permitted
somatostatin receptor detection with clinically relevant im-
plications for the diagnosis and therapeutic management of
tumors. Although the sst2 receptors found in the tumors are
usually membrane bound when patients are not receiving
somatostatin analogue treatment, it has recently been pos-
sible to detect intracellular sst2 in tumor cells of patients
treated with octreotide.9 However, it is not known whether
intracellular sst2 represents activated sst2 internalized after
octreotide therapy or newly synthesized receptors that are
unable to traffic to the cell surface. Similarly, it is not known
whether membrane-bound sst2 can be found in an acti-
vated form in human tumor tissues.
Activation of G-protein–coupled receptors by agonist bind-
ing at the plasmamembrane causes rapid phosphorylation of
the activated receptors by G-protein–coupled receptor ki-
nases, a critical step for subsequent receptor internalization.10
In fact, somatostatin treatment of cultured cells stimulates the
phosphorylation of the sst2A receptor within seconds and re-
ceptor phosphorylation is maintained for at least 2 hours in the
continued presence of hormone.11–13 Moreover, sst2A recep-
tors have been phosphorylated in tumors that produce soma-
tostatin, presumably as the result of autocrine stimulation.14
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receptors, and G-protein–coupled receptors more generally,
in humans.
It would be of great interest to be able to specifically identify
sst2 in its activated form in tumor samples (namely, as phos-
phorylated sst2). Such IHC detection of sst2 after agonist ac-
tivation in patients’ tumors could have potential clinical impli-
cations (eg, to understand how tumors escape octreotide
responsiveness). The residues in the sst2A receptor that be-
come phosphorylated on hormone stimulation have been re-
cently identified, and antibodies specific for the phosphory-
lated forms of the receptor havebeendeveloped.13,15 The aim
of the present study was to use one of these antibodies (Ra-
1124), known to be specific for the sst2 receptor phosphory-
lated at Ser341/343,13 to investigate the effect of octreotide
treatment on receptor phosphorylation in patient tumors.
Therefore, we compared the phosphorylation of the sst2 re-
ceptor in a broad sample of receptor-expressing tumors ob-
tained fromoctreotide-treatedanduntreatedpatientswith gas-
troenteropancreatic tumors.
Materials and Methods
Formalin-fixed and fresh-frozen tissue samples from surgi-
cally resected neuroendocrine tumors expressing sst2 re-
Table 1. Phosphorylated and Nonphosphorylated sst2 Receptor
Naïve Patients
Patient
code Tumor type
OCT long-term
therapy
OC
OCT Treated
1 NET (pancreatic) LAR, 20 mg, 3 weeks
preoperatively
200
p
2 NET (bronchial) LAR, 20 mg, 3 weeks
preoperatively
200
p
3 NET (pancreatic) No 200
4 NET (pancreatic) No 200
5 NET (pancreatic) No 200
6a† NET (pancreatic,
primary)
No 200
6b† NET (pancreatic,
liver metastases)
No 200
7 NET (pancreatic) No 200
8 NET (pancreatic) No 200
9 NET (pancreatic) No 200
10 NET (pancreatic) No 200
OCT Untreated
11 NET (pancreatic) No No
12 NET (bile duct) No No
13 NET (ileal) No No
14 NET (liver) No No
15 NET (pancreatic) No No
16 NET (ileal) No No
17 NET (ileal) No No
*The 200 g s.c. dose was given at the initiation of narcosis.
†Samples 6a and 6b are from the same patient.
ARG, somatostatin receptor autoradiography; internal, internalized retested; OCT, octreotide; P-sst2, Ser341/343-phosphorylated sst2 receptor; 
receptors (8000 dpm/mg tissue).ceptors were used. The tumor samples originated from pa-
tients who had received an i.v. octreotide infusion (200
g/hour) during surgical resection plus 20 mg of octreotide,
long-acting release (LAR), 3 weeks before surgery, from
patients who had received 200 g of octreotide s.c. at the
start of surgery, or, as controls, from patients who had not
been in contact with octreotide before or during surgery.
Protocol variability occurred because of patient-based and
surgery-dependent situations and included a variable route
of octreotide administration (i.v. injection, s.c. injection, or
LAR) and variable intervals between octreotide injection
and tumor removal. Written informed consent was available
for all patients. The present study conformed to the ethical
guidelines of the Institute of Pathology, University of Berne
and University Hospital of Berne, Berne, Switzerland, and
was reviewed by the Institutional Review Board.
sst2 IHC Data
The sst2 receptors were detected using IHC, as previously
described.7,8,16–18 All samples were tested with the rabbit
monoclonal antibody UMB-1 (SS-8000RM; Biotrend GmbH,
Cologne, Germany).6,7 Formalin-fixed, paraffin-embedded
tissue sections (4m thick) were used. The antigen retrieval
method for UMB-1 IHC was boiling in the microwave in the
n Neuroendocrine Tumor Samples from OCT-Treated and OCT-
eratively/
ratively ARG sst2 (UMB-1 IHC)
Phospho-sst2
(Ra-1124 IHC)
r infusion
tive
 Mostly internal sst2 Mostly internal P-sst2
r infusion
tive
NT Mostly internal sst2 Mostly internal P-sst2
.*  Mostly internal sst2 Mostly internal P-sst2
.*  Internal  membrane
sst2
Mostly internal P-sst2
.* NT Internal  membrane
sst2
Mostly internal P-sst2
.*  Internal  membrane
sst2
Internal  membrane
P-sst2
.*  Internal  membrane
sst2
Internal  membrane
P-sst2
.*  Membrane  internal
sst2
Membrane  internal
P-sst2
.*  Mostly membrane
sst2
Few membrane P-sst2
.*  Mostly membrane
sst2
Few membrane P-sst2
.*  Mostly membrane
sst2
P-sst2 undetectable
 Membrane sst2 P-sst2 undetectable
NT Membrane sst2 P-sst2 undetectable
 Membrane sst2 P-sst2 undetectable
 Membrane sst2 P-sst2 undetectable
 Membrane sst2 P-sst2 undetectable
 Membrane sst2 P-sst2 undetectable
NT Membrane sst2 P-sst2 undetectable
membrane, membranous receptor; NET, neuroendocrine tumor; NT, notStatus i
T preop
periope
g/hou
eriopera
g/hou
eriopera
g s.c
g s.c
g s.c
g s.c
g s.c
g s.c
g s.c
g s.c
g s.c
ceptor;
, a density of 4567 dpm/mg tissue; , high-density of somatostatin
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AJP May 2012, Vol. 180, No. 5presence of a 5% urea buffer (pH 9.5). The antibody was
used at a dilution of 1:100. The secondary antibody was a
biotinylated goat anti-rabbit Ig (Dako, Baar, Switzerland)
(1:200 dilution). Antibody binding was visualized using the
VECTASTAIN Elite ABC Kit (Vector, Burlingame, CA). Stain-
ing was performed with diaminobenzidine, and counter-
staining was performed with hemalum. For specificity con-
trol, the primary antibody was preadsorbed with 100 nmol/L
of the corresponding antigen peptide.
Phosphorylated sst2 IHC
Ser341/343-phosphorylated sst2 receptors were de-
tected by IHC, using the Ra-1124 antibody, as recently
reported.13 The same protocol was used as for sst2 IHC
(previously described).
Receptor Autoradiography
In all cases with available fresh-frozen tumor tissues,
somatostatin receptor autoradiography was performed,
as previously described,19 using 125Iodine-Tyrosine3-oc-
treotide (125I-Tyr3-octreotide) as the radioactive ligand.
Receptor Purification and Immunoblot Analysis
Frozen tumor samples were homogenized using a Whea-
ton Tenbroeck Tissue Grinder in homogenization buffer (10
A B Cmmol/L Tris-HCl, 5 mmol/L EDTA, 3 mmol/L EGTA, and 250
mmol/L sucrose; pH 7.6) with protease and phosphatase
inhibitors (1 mmol/L phenylmethylsulfonyl fluoride, 10
g/mL soybean trypsin inhibitor, 10 g/mL leupeptin, 50
g/mL bacitracin, 10 mmol/L sodium pyrophosphate, 10
mmol/L sodium fluoride, 0.1 mmol/L sodium vanadate, and
100 nmol/L okadaic acid). After a low-speed centrifugation
at 600  g for 10 minutes, the supernatant was centrifuged
at 100,000  g for 60 minutes. The pelleted membranes
were solubilized in cold lysis buffer (150 mmol/L NaCl and
20mmol/L HEPES, pH 7.4; 5 mmol/L EDTA, 3 mmol/L EGTA
containing 4mg/mL dodecyl maltoside, and protease and
phosphatase inhibitors) for 60 minutes at 4°C. After centrif-
ugation at 10,000 g for 10 minutes, the solubilized recep-
tors were purified by wheat germ agglutinin agarose
adsorption, as previously described.14,18 The entire prepa-
ration of purified receptors from each sample was sub-
jected to SDS-PAGE, transferred to a polyvinylidene difluo-
ride membrane, and immunoblotted with the phospho-
sst2A receptor antibody Ra-1124. The blots were then
stripped and reprobed with a phosphorylation-independent
sst2A antibody (NB100-74537; Novus Biologicals, Littleton,
CO) to demonstrate the presence of the receptor.
Immunofluorescence Microscopy
Immunofluorescence microscopy using the human em-
bryonic kidney cell line HEK293 expressing the T7-
Figure 1. sst2 IHC (UMB-1) and phosphory-
lated sst2 IHC (Ra-1124) on successive sections
of tumor tissue from three patients treated with
octreotide during surgery. Data include patients
3 (top row), 6b (middle row), and 7 (bottom
row). A: UMB-1 IHC. B: Ra-1124 IHC. C: Ra-
1124 IHC in the presence of excess of the phos-
phorylated antigen peptide. D: Ra-1124 IHC in
the presence of excess of the nonphosphory-
lated antigen peptide. Patient 3 shows predom-
inantly internalized sst2 and phosphorylated
sst2, whereas patient 6b has a mixture of mem-
branous and internalized sst2 and phosphory-
lated sst2. Patient 7 shows a predominantly
membranous sst2 and phosphorylated sst2. In all
cases, the phosphorylated sst2 staining is abol-
ished with the phosphorylated antigen peptide
but not with the nonphosphorylated antigen
peptide. Scale bar  0.01 mm.D
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performed as previously described.9,20 Briefly, HEK-sst2
cells were grown overnight on poly-D-lysine (20 g/mL)
(Sigma-Aldrich, St. Louis, MO) coated 35-mm four-well
A B
Figure 2. IHC detection of sst2, but not of phosphorylated sst2, in two octreotide-
naïve patients. Successive sections are shown for patients 14 (top row) and 11
(bottom row). A: UMB-1 IHC. B: Ra-1124 IHC. Scale bar  0.01 mm.
Pancreatic islets Duode
B
C D
A E
Gplates (Cellstar; Greiner Bio-One GmbH, Frickenhausen,
Germany). The cells were treated at 37°C in growth me-
dium with 1 mol/L octreotide or Coy-14 (BIM-23A180)21
(provided by Dr. Jean Rivier, Salk Institute, San Diego,
CA) for the times indicated, and subsequently processed
for immunofluorescence microscopy. The sst2-specific
antibody UMB-1 (SS-8000RM; Biotrend GmbH, Cologne,
Germany), used at a dilution of 1:25, or the phospho-site-
specific sst2 antibody Ra-1124,13 used at a dilution of
1:500, were used as primary antibodies. As specificity
control for Ra-1124, the antibody was preincubated with
an excess of either the phosphorylated antigen peptide
or with the nonphosphorylated antigen peptide before
applying to the cells. The Alexa Fluor488 goat anti-rabbit
IgG (HL) antibody (Molecular Probes, Inc., Eugene, OR),
diluted 1:600, was used as secondary antibody. Immuno-
fluorescence staining of the cells was imaged using a Leica
DM RB immunofluorescence microscope (Leica, Wetzlar,
Germany) and anOlympus DP10 camera (Olympus, Tokyo,
Japan).
Immunofluorescence Confocal Microscopy
HEK293 cells were transfected with hemagglutinin-
tagged human-sst2A plasmid DNA and a clonal cell line
that stably expressed the receptor (HEK-hsst2A cells)
was selected by serial dilution. The localization of human
sst2A receptors was examined in these cells before and
after treatment with somatostatin, following a modified
protocol that was previously described.22 Briefly, HEK-
sst2A cells were incubated with mouse monoclonal an-
ti-HA antibody (1:1000; Covance, Berkeley, CA) at room
temperature for 1 hour to label surface receptors and
then treated with 100 nmol/L SS14 or octreotide at 37°C
for various time intervals. After agonist stimulation, cells
were incubated for 1 hour with the Ra-1124 antibody
(1:1000) to label phosphorylated receptor. Subsequently,
E cells
Figure 3. The sst2 and phosphorylated sst2 IHC
of successive sections of pancreas (A–D) from an
octreotide-treated patient (A and B) and an oc-
treotide-naïve patient (C andD) and of duodenum
(E–H) from an octreotide-treated patient (E and F)
and an octreotide-naïve patient (G andH). A, C, E,
and G: UMB-1 IHC showing sst2-positive cells in
all cases. B,D, F, andH: Ra-1124 IHC showing the
presence of phosphorylated sst2 in the octreotide-
treated patients only (B and F). The same duode-
nal neuroendocrine cells are positive for sst2 and
phosphorylated sst2 in the treated patient, whereas
the two sst2-positive cells are not stained for the
phosphorylated sst2 in the naïve patient. Scale
bar  0.01 mm. NE, neuroendocrine.nal N
F
H
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Invitrogen, Eugene, OR) and dichlorotriazinyl amino fluo-
rescein–conjugated AffiniPure F(ab’)2 fragment donkey
anti-rabbit IgG (HL) (1:300; Jackson ImmunoResearch
Labs, West Grove, PA) were used as secondary antibod-
ies. Cells were further stained with the nucleic acid stain,
DAPI (Invitrogen), and mounted with ProLong Gold anti-
fade mounting reagent (Invitrogen). Fluorescent images
were viewed with a 60 objective using an A1R confocal
microscope (Nikon, Melville, NY) with an excitation filter
of 488 nm and an emission filter of 500 to 550 nm for
dichlorotriazinyl amino fluorescein, an excitation filter of
561 nm and an emission filter of 570 to 620 nm for Alexa
Fluor568, and an excitation filter of 358 nm and an emission
filter of 461 nm for DAPI. Images from at least 8 to 10 cells
were recorded in each treatment group in each experiment.
The images shown are representative of observations in
three independent experiments. The specificity of the anti-
bodies was validated by testing nontransfected HEK293
cells stimulated with 100 nmol/L somatostatin for 30 minutes
and somatostatin stimulated HEK-hsst2A cells incubated
with Ra-1124 antibody that had been pretreated with 100
nmol/L antigen peptide. No staining was detected with Ra-
1124 in either condition.
Results
The autoradiographic and IHC data are summarized in
Table 1. Tumor tissue was obtained from a total of 17
patients. Ten of them were treated with octreotide during
the surgical resection of their tumors, two receiving a
perioperative infusion of 200 g/hour octreotide plus 20
mg octreotide LAR 3 weeks before surgery and the other
eight receiving 200 g octreotide s.c. perioperatively.
Furthermore, there were seven control patients who had
not received octreotide at any time before or during sur-
gery. All patients, treated and nontreated, had tumors
with a high expression of sst2 receptors. In all those
patients in which receptor autoradiography was feasi-
ble because of the availability of fresh-frozen tissue,
the tumors showed high somatostatin binding. In addi-
tion, all tumors were strongly positive for sst2 IHC, as
performed with the sst2-specific UMB-1 antibody. Al-
though all seven control samples showed strong mem-
branous sst2 staining, the 10 octreotide-treated tumors
had internalized sst2 to varying degrees, ranging from
mostly internalized sst2 to mostly membranous sst2, as
previously reported.9
IHC using Ra-1124 specific for Ser341/343-phosphor-
ylated sst2 showed absence of staining in all tumors from
octreotide-naïve patients, whereas Ra-1124 staining was
visible to varying degrees in all but one of the tumors from
treated patients. Phosphorylated sst2 was seen as mostly
internalized in five cases, equally internalized and membra-
nous in two samples from the same patient, and predomi-
nantly membranous in three cases. Figure 1 illustrates the
results. First, it shows two typical octreotide-treated cases:
one case shows predominantly internalized sst2 receptors
identified as activated, phosphorylated receptors with Ra-
1124; and the other case shows membranous and internal-ized sst2, also identified in both locations as Ser341/343-
phosphorylated sst2 with Ra-1124. Second, it also shows
a more rare condition of an octreotide-treated case with a
predominance of membranous sst2, also detectable in
the phosphorylated state at the membrane. Phospho-
antibody specificity was demonstrated by showing lack
of staining in the presence of the phosphorylated antigen
peptide but no blockage in presence of the nonphospho-
rylated antigen peptide. Figure 2 shows absence of
Ser341/343-phosphorylated sst2 in tumors of octreotide-
naïve patients who express a high density of membra-
nous sst2.
Interestingly, in tumor samples containing adjacent
nonneoplastic pancreas or gastrointestinal tissue, we
also observed phosphorylated sst2 in these normal tis-
sues of octreotide-treated patients. Figure 3 shows phos-
phorylated sst2 in a pancreatic islet from an octreotide-
treated patient, whereas no phosphorylated sst2 is
detected in sst2-expressing islets in an octreotide-naïve
patient. The same result is found in duodenal neuroen-
docrine cells: the normal duodenum of an octreotide-
treated patient reveals numerous neuroendocrine cells
positive for the phosphorylated sst2, whereas no such
cells are seen in a naïve patient. As a reference, the
pancreas and duodenum of octreotide-naïve patients al-
ways had sst2-expessing cells, as detected by UMB-1
staining (Figure 3).
Figure 4 shows a Western blot analysis of tumors from
Figure 4. Phosphorylation of the sst2A receptor in human tumors. Mem-
branes from the tumor samples shown (octreotide-treated patients 1, 3, 6,
and 9 and untreated control patient 14) were prepared as described in
Materials and Methods and purified by adsorption to wheat germ–agglutinin
(WGA) agarose. WGA-adsorbed proteins were analyzed by SDS-PAGE and
immunoblotted with the Ra-1124 antibody, which is specific for phospho-
Ser341/343 in the carboxy-terminus of the sst2A receptor. Blots were then
stripped and reprobed with the phosphorylation state–independent sst2A-
specific antibody (NB100-74537) to determine the level of receptor expres-
sion in the different tumors.four octreotide-treated and one naïve patient. Although sst2
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rylation-independent antibody (NB100-74537), the phos-
phorylated sst2 is detected with Ra-1124 only in the four
treated patients but not in the octreotide-naïve patient.
Immunofluorescence microscopy studies were per-
formed with the phospho-site-specific sst2 antibody Ra-
112413 using HEK293 cells stably expressing the sst2
receptor to compare with the data in patient tissues and
to have a cellular basis to understand them. Figure 5A
shows double labeling with the Ra-1124 antibody for the
phosphorylated receptor and the HA antibody, which
detects both phosphorylated and nonphosphorylated re-
ceptors. Ra-1124 produced no signal without agonist
stimulation, although the nonphosphorylated cell surface
receptors were readily visualized with anti-HA antibody.
This observation is consistent with the absence of
Ser341/343 sst2A receptor phosphorylation in unstimu-
lated cells.13,15 After treatment with SS14 for 30 minutes,
Ra-1124 and anti-HA reactivity are colocalized in intra-
cellular vesicles, showing that the phosphorylated re-
ceptor has been internalized. The Ra-1124 staining is
specific because the signal is abolished with the phos-
phorylated antigen peptide, whereas nonphosphory-
lated peptide does not eliminate the signal (data not
shown).
To investigate the distribution of phosphorylated re-
ceptors after different times of stimulation, cells were
incubated with or without 1 mol/L octreotide for 10 sec-
0 s 10 s 10 min 30 m
1 µM Octreotide
U
M
B
-1
R
a-
11
24
B
Ra-1124
Ra-1124 + anti-HA 
SS14 (min)
Phospho-Ag peptide
0 30
- -
Aonds, 10 minutes, and 30 minutes (Figure 5B). Stainingwith UMB-1 shows that, without agonist stimulation, the
receptor is localized at the plasma membrane; and after
stimulation with octreotide, the receptor internalizes into
the cell, detectable after 10 minutes as a perinuclear dot.
By using Ra-1124, no Ser341/343-phosphorylated recep-
tors are detected without agonist stimulation. However,
already 10 seconds after octreotide stimulation, the phos-
phorylated sst2 is detectable at the plasma membrane;
and after 10 minutes, it is localized mostly within the cell
and is detected as a perinuclear dot. Moreover, the es-
tablished sst2 antagonist Coy-1421 does not induce sst2
phosphorylation when applied to the cells at a concen-
tration of 1 mol/L, consistent with previous results.13
Discussion
To our knowledge, this is the first study showing that
octreotide treatment leads to agonist-induced phosphor-
ylation of sst2 receptors in patients with sst2-expressing
neuroendocrine tumors. The main findings are as follows:
i) In the absence of stimulation, the receptor is not phos-
phorylated and is found exclusively at the cell surface,
whereas octreotide treatment produces both sst2 phos-
phorylation and internalization. ii) Activated, phosphory-
lated sst2 can be detected both at the plasma membrane
and intracellularly. The intracellular receptors must orig-
inally have been at the cell surface for octreotide to have
30 min
1 µM Coy-Antag.
30
+
Figure 5. Trafficking of the phosphorylated re-
ceptor after agonist stimulation. A: HEK293T cells
stably expressing HA-tagged hsst2A receptors
(HEK-sst2A) were preincubated with anti-HA anti-
body (red) to label cell surface receptors and
then incubated at 37°C for 30 minutes without or
with 100 nmol/L SS14. After fixation and per-
meabilization, cells were incubated with the an-
ti-pS341/343 antibody Ra-1124 (green) to iden-
tify phosphorylated receptors, incubated with
DAPI (blue) to identify nuclei, and processed for
confocal microscopy, as described in Materials
and Methods. Images were acquired with a
Nikon A1R confocal microscope. Colocalized
(yellow) proteins are visible in endocytic vesi-
cles throughout the cytoplasm. Immunolabeling
of phosphorylated receptor with Ra-1124 is pre-
vented by preincubation of this antibody with
the phosphorylated antigen peptide (right
panel). The images shown are representative of
results from at least three independent experi-
ments. B: Detection of octreotide-stimulated in-
ternalization of the phosphorylated sst2. HEK-
sst2 cells were treated with 1 mol/L octreotide
for 0 seconds, 10 seconds, 10 minutes, and 30
minutes or with the sst2 receptor antagonist Coy-
1421 for 30 minutes. After ligand incubation, the
cells were processed for immunocytochemistry,
as described in Materials and Methods, using
either UMB-1 to detect sst2 receptor or Ra-1124
to detect phosphorylated sst2. The sst2 receptor
antagonist Coy-14 is not able to stimulate recep-
tor phosphorylation and internalization.instimulated their phosphorylation. iii) In vitro data show that
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sure. iv) At high magnification, the phosphorylated, inter-
nalized sst2 shows an intracellular distribution pattern
corresponding to localization in endosomal struc-
tures.20,23–25
The degree of receptor phosphorylation and the cellu-
lar localization of the phosphorylated sst2 varies substan-
tially between patients. A good correlation was found
between sst2 internalization and Ser341/343 phosphory-
lation of the receptor. A high-dose octreotide treatment
combining octreotide LAR and octreotide infusion26 dur-
ing surgical resection consistently leads to the accumu-
lation of intracellular, phosphorylated receptors that can
be detected by IHC with Ra-1124. However, with only 200
g octreotide given s.c. at the start of surgery, a variety of
sst2 phosphorylation/internalization patterns are ob-
served, ranging from almost complete receptor phos-
phorylation/internalization in some cases to only focal or
even absent phosphorylation/internalization. Also, a het-
erogeneous distribution of tumor cells containing the
phosphorylated receptors can sometimes be observed,
with cells containing phosphorylated sst2 receptors lo-
cated next to cells without such receptors. Similar find-
ings were previously reported for cells with membrane-
bound sst2.7 The diversity in patterns may be the result of
the fact that the 200-g s.c. octreotide is a submaximal
dose9,26 and may not be sufficient to trigger a complete
and long-lasting Ser341/343 phosphorylation/internaliza-
tion effect on the sst2 in all tumors or may be the result
of other aspects of tumor function. The octreotide con-
centration at the target will depend on numerous sys-
temic and local factors, including the performance of
the cardiovascular system and local tumor perfusion,
and the time elapsing between s.c. application and
tumor resection.9
The specificity of immunostaining is confirmed by us-
ing Western blot analysis in selected tumor cases. Immu-
noblotting with the Ra-1124 showed a specific band cor-
responding to the sst2 receptor also detected by a
phosphorylation-independent receptor antibody. More-
over, the phosphorylated sst2 immunostaining is always
abolished in the presence of an excess of the phosphor-
ylated antigen peptide but not with the nonphosphory-
lated antigen peptide. These results further show that the
intracellular staining seen by IHC represents specific ac-
tivated sst2 receptors.
Interestingly, there are a few tumor cases clearly
showing cell surface staining of the phosphorylated
sst2, paralleling our observations in vitro: using immu-
nofluorescence microscopy, HEK-sst2 cells show
phosphorylation of the sst2 receptors at the plasma
membrane after 10 seconds of octreotide exposure.
Later, the phosphorylated receptor is internalized, with
little phosphorylated sst2 left on the membrane. Thus,
although receptor internalization follows receptor phos-
phorylation in most instances, receptor internalization
does not occur efficiently in all tumors, despite strong
receptor phosphorylation. Previous studies13 have shown
that reversal of Ser341/343 phosphorylation after removal
of ligand occurs only after the receptor has internalized.
Because receptors must be dephosphorylated to be ableto respond again to hormone stimulation, the inability to
internalize receptors may lead to a resistance to further
agonist stimulation.
Some patients present a phenomenon of escape after
long-term therapy with somatostatin analogues (ie, they
stop responding to somatostatin analogue stimula-
tion).27,28 The underlying mechanisms are not estab-
lished. By assessing the localization and activation state
of sst2 receptors resistant to somatostatin analogues in
tissue samples from sensitive and resistant patients, it
may be possible to determine whether receptor activation
or internalization is impaired in this situation.
The novel approach described in this study will in-
crease our understanding of the molecular behavior of
somatostatin receptors in tumors and provide insights
into the mechanisms of receptor activation in vivo that are
likely to be helpful for the use of somatostatin analogues
in the diagnosis and treatment of neuroendocrine tumors.
Although, in the past decade, the detection by IHC of
nonactivated tumoral sst2 has proved an important pa-
rameter for the design of diagnostic and therapeutic
strategy, the assessment of sst2 activation by phospho-
sst2 IHC likely in the future is to provide important insights
into the nature and causes of variability in sst2 activation
either on agonist stimulation or, alternatively, constitutive
phosphorylation, as reported for estrogen receptors.29
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